Literature DB >> 8097733

A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention.

W L Hasler1, H C Soudah, C Owyang.   

Abstract

BACKGROUND: Octreotide, a somatostatin analogue, has antinociceptive activity in several models. We studied whether octreotide modifies perception of rectal distention in healthy volunteers and examined its mechanism of action.
METHODS: Octreotide (100 micrograms, subcutaneously) and placebo were injected in double-blind fashion. Rectal balloons measured volumes that evoked increasing levels of perception. Octreotide's effects on rectal sensation were compared with actions on rectal resistance, rectal motor activity, afferent and efferent anal activity, and somatic perception.
RESULTS: After octreotide administration, threshold perception, pressure, urgency, and maximal tolerated volume were reported at 62 +/- 4, 185 +/- 11, 269 +/- 17, and 362 +/- 25 mL, which were greater than after administration of placebo (25 +/- 4, 95 +/- 9, 153 +/- 10, and 211 +/- 13 mL, P < 0.01). Rectal pressures, which increased from 9.2 +/- 1.2 mm Hg at 30 mL to 20.2 +/- 1.7 mm Hg at 180 mL after administration of placebo, were not modified by octreotide; this shows a lack of effect on rectal resistance. However, in addition to enhancing volumetric tolerance, maximally tolerated pressures were increased to 42.4 +/- 5.1 mm Hg (P < 0.01) by octreotide. Octreotide increased phasic rectal contractions but did not change anal pressures or block the rectoanal inhibitory reflex, confirming that local rectal reflex arcs are unaffected. Perception of thermal or electrical cutaneous stimulation was unaffected by octreotide showing selectivity for visceral afferent pathways.
CONCLUSIONS: Octreotide reduces sensation of rectal distention via inhibition of visceral afferent pathways. In contrast, afferent pathways involved in local reflexes and cutaneous perception are not inhibited by octreotide.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097733     DOI: 10.1016/0016-5085(93)90347-f

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  27 in total

1.  Some of the challenges in drug development for irritable bowel syndrome.

Authors:  E A Mayer
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 2.  The epidural and intrathecal administration of somatotrophin-release inhibiting factor: native and synthetic analogues.

Authors:  D P Beltrutti; S Moessinger; G Varrassi
Journal:  Curr Rev Pain       Date:  2000

3.  Chronic Intestinal Pseudo-obstruction.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

Review 4.  Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls.

Authors:  M Camilleri
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

5.  Effects of octreotide on responses to colorectal distension in the rat.

Authors:  X Su; M B Burton; G F Gebhart
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

6.  Peptidergic innervation of the internal anal sphincter in Hirschsprung's disease.

Authors:  B Husberg; M Schultzberg
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

7.  Augmented Visceral Perception.

Authors:  William L. Hasler
Journal:  Curr Treat Options Gastroenterol       Date:  2001-08

Review 8.  Octreotide in gastrointestinal motility disorders.

Authors:  C Owyang
Journal:  Gut       Date:  1994       Impact factor: 23.059

9.  Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome.

Authors:  Alexandru Gaman; Maria Cristina Bucur; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2009-05-01       Impact factor: 4.409

10.  Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans.

Authors:  A Foxx-Orenstein; M Camilleri; D Stephens; D Burton
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.